Page 17

SECONDARY Segments: Business

Revenue

Normalised EBITA 25,7%

Operating profit

22,3%

22,0%

74,3% 77,7%

78,0%

Pharmaceutical

Consumer

The table set out below records the anticipated launches of Aspen’s new products in the South African market by therapeutic class as at 30 June 2006. 0 – 2 years

3 – 5 years

Total

Number

IMS

Number

IMS

Number

IMS

of

value

of

value

of

value

dossiers

R’million

dossiers

R’million

dossiers

R’million

16

167

25

178

41

345

8

84

13

114

21

198

Anti-infectives

14

64

38

412

52

476

Cardiovascular

18

152

35

570

53

722

Respiratory

17

64

8

102

25

166

Musculo-skeletal

2

15

8

89

10

104

Endocrine

8

106

22

182

30

288

Dermatologicals

1

12

13

93

14

105

7

70

7

70

7

62

7

62

Therapeutic class Central nervous system Alimentary and metabolism

Systemic hormones Antineoplastics and immunomodule Various others TOTAL

8

12

3

24

11

36

92

676

179

1 896

271

2 572

Notes 1. Values stated in the table have been derived from IMS Health (Pty) Ltd (“IMS”). IMS is an independent measure of the private pharmaceutical market of South Africa. The IMS value, as set out in the table above, records the value of sales of the originator’s products. In assessing the potential value to Aspen of the dossiers to be launched, the following needs to be taken into consideration: i) The generic product of an original trades at a discount to the original product. ii) The entry of generic products to the market will result in greater competition. 2. The table relates to the South African private market only. The South African tender (public sector) market has been omitted entirely. 3. Products which are already registered are not included. 4. Not all of the dossiers have been submitted to the South African Medicines Control Council (“MCC”).

13

Aspen Annual Report 2006

Profile for Aspen Holdings

Aspen Annual Report 2006  

Aspen Annual Report 2006